Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.…
Cogent Biosciences (COGT) Stock Looks Fully Priced Against Its Asset Base
Cogent Biosciences (NASDAQ: COGT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 258 employees.
The shares were at 26.72 USD on 20 November 2026, up 80.3% over 52 weeks. Its 52-week range is 26.36 USD to 43.73 USD: the price is 38.9% below the high and 1.3% above the low.
Its market capitalisation is 4.65B USD.
Cogent Biosciences reports return on equity of -51.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 546.91M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 55.82 USD is 108.9% above the current price. The next earnings report is expected on 16 February 2027.